Kirsten Fischer
A5061682665- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Advanced Breast Cancer Therapies
- Chronic Myeloid Leukemia Treatments
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- American Constitutional Law and Politics
- Glycosylation and Glycoproteins Research
- Race, History, and American Society
- Cancer-related gene regulation
- Gastrointestinal Tumor Research and Treatment
- Monoclonal and Polyclonal Antibodies Research
- RNA modifications and cancer
- Colonialism, slavery, and trade
- Methemoglobinemia and Tumor Lysis Syndrome
- Historical Gender and Feminism Studies
- American History and Culture
- Acute Myeloid Leukemia Research
- Telomeres, Telomerase, and Senescence
- Archaeology and Natural History
- Genomic variations and chromosomal abnormalities
- Ocular Surface and Contact Lens
- Neural Networks and Applications
University Hospital Cologne
2016-2025
Düsseldorf University Hospital
2019-2024
Heinrich Heine University Düsseldorf
2019-2024
University of Cologne
2015-2024
Integrated Oncology (United States)
2014-2023
University of Mines and Technology
2022
Centrum für Integrierte Onkologie
2013-2021
Universität Ulm
2016-2021
AbbVie (United States)
2021
Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases
2014-2019
The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients previously untreated chronic lymphocytic leukemia (CLL) but not those coexisting conditions. We investigated the benefit of type 2, glycoengineered obinutuzumab (also known as GA101) compared that each chlorambucil, CLL and conditions.We randomly assigned 781 a score higher than 6 on Cumulative Illness Rating Scale (CIRS) (range, 0 56,...
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy combination other agents CLL and coexisting conditions is not known.In this open-label, phase 3 trial, we investigated fixed-duration treatment obinutuzumab previously untreated conditions. Patients a score of greater than 6 on the Cumulative Illness Rating Scale (scores range from 0 to 56, higher scores indicating more impaired function organ systems) or calculated...
Purpose To determine the clinical significance of flow cytometric minimal residual disease (MRD) quantification in chronic lymphocytic leukemia (CLL) addition to pretherapeutic risk factors and compare prognostic impact MRD between arms German CLL Study Group CLL8 trial. Patients Methods levels were prospectively quantified 1,775 blood bone marrow samples from 493 patients randomly assigned receive fludarabine cyclophosphamide (FC) or FC plus rituximab (FCR). categorized by into low- (<...
We investigated the safety and efficacy of bendamustine rituximab (BR) in previously untreated patients with chronic lymphocytic leukemia (CLL).In all, 117 patients, age 34 to 78 years, 46.2% at Binet stage C, 25.6% 70 years or older received BR chemoimmunotherapy for first-line treatment CLL. Bendamustine was administered a dose 90 mg/m(2) on days 1 2 combined 375 day 0 first course 500 during subsequent courses up six courses.Overall response rate 88.0% (95% CI, 80.7% 100.0%) complete...
The objective of this trial was to evaluate safety and efficacy bendamustine combined with rituximab (BR) in patients relapsed and/or refractory chronic lymphocytic leukemia (CLL).Seventy-eight patients, including 22 fludarabine-refractory disease (28.2%) 14 (17.9%) deletion 17p, received BR chemoimmunotherapy. Bendamustine administered at a dose 70 mg/m(2) on days 1 2 375 day 0 the first course 500 during subsequent courses for up six courses.On basis intent-to-treat analysis, overall...
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden coexisting conditions) advanced chronic lymphocytic leukemia (CLL) have been lacking. Download PDF the Research Summary. In phase 3, open-label trial, we randomly assigned, 1:1:1:1 ratio, CLL who did not TP53 aberrations to receive six cycles chemoimmunotherapy (fludarabine–cyclophosphamide–rituximab or bendamustine–rituximab) 12 venetoclax–rituximab,...
The CLL14 study has established one-year fixed-duration treatment of venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic lymphocytic leukemia. With all off at least three years, we report a detailed analysis minimal residual disease (MRD) kinetics long-term outcome treated in the study.Patients were randomly assigned to receive six cycles 12 or chlorambucil (Clb-Obi). Progression-free survival (PFS) was primary end point. Key secondary points included rates...
Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment chronic lymphocytic leukemia (CLL) are limited. In this open-label parallel-group phase-3 study, 432 patients previously untreated CLL were randomized (1:1) to receive either 1-year venetoclax-obinutuzumab (Ven-Obi, 216 patients) or chlorambucil-Obi (Clb-Obi, therapy (NCT02242942). The primary endpoint was investigator-assessed progression-free survival...
In the primary analysis report of GAIA/CLL13 trial, we found that venetoclax-obinutuzumab and venetoclax-obinutuzumab-ibrutinib improved undetectable measurable residual disease (MRD) rates progression-free survival compared with chemoimmunotherapy in patients previously untreated chronic lymphocytic leukaemia. However, to our knowledge, no data on direct comparisons different venetoclax-based combinations are available.
Purpose To determine the value of minimal residual disease (MRD) assessments, together with evaluation clinical response in chronic lymphocytic leukemia according to 2008 International Workshop on Chronic Lymphocytic Leukemia criteria. Patients and Methods Progression-free survival (PFS) overall 554 patients from two randomized trials German CLL Study Group (CLL8: fludarabine cyclophosphamide [FC] v FC plus rituximab; CLL10: rituximab bendamustine rituximab) were analyzed MRD assessed...
Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence AF in a general cohort chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated prevalence at CLL diagnosis and during follow-up 2444 with newly diagnosed CLL. A prior history was present 148 (6.1%). Among 2292 without AF, 139 (6.1%) developed incident (incidence approximately 1%/year). Older age (p < .0001), male sex = .01), valvular heart disease .001), hypertension...